Detailed information on patterns in the use of intravenous methylprednisolone pulse (IVMP) therapy in moderate juvenile dermatomyositis. (A) Doses employed for the individual infusions, (B) the duration of each individual therapy, (C) the overall duration of IVMP therapy and (D) the frequency of IVMP therapy. Abbreviations: IVMP, intravenous methylprednisolone pulse. (JPG 273 kb
The present guidelines on dermatomyositis (DM) represent an excerpt from the interdisciplinary S2k g...
Figure S2. Biological therapy: time to introduction and remission rate. Disease duration before intr...
Appendix of longitudinal analysis methods for prognosis study in rheumatic diseases. (DOCX 1112 kb
Detailed information on patterns in the use of high-dose glucocorticoid therapy in moderate juvenile...
CARRA survey: Use of Biologics in Juvenile Dermatomyositis. Appendix B Second CARRA JDM Survey: Use ...
Disease Characteristics of 45 Patients with Juvenile Dermatomyositis. (DOCX 27 kb
Additional file 1: Fig. 1s: Changes of BMI percentile in JDM patients over study duration (60 months...
Tables S1. Intravenous pulse methylprednisolone use and dosage. Table S2. Cyclophosphamide and oral ...
Additional file 2: Fig. 2s: Changes of Total body fat (TBF) percentile in JDM patients over study du...
Background: Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy in childhood and...
Abstract Background Juvenile Dermatomyositis (JDM) is a rare pediatric autoimmune disease with broad...
Table with total number of AEs by MedDRA SOC for retrospective and prospective visits in the Pharmac...
Juvenile dermatomyositis (JDM) is a rare, severe, autoimmune disease characterized by a small-vessel...
Figure S1A. VAS and score of ISG15, HIF1α and VEGF in DM patients. “Severity” of tissue affection in...
Objective: To determine the clinical profile and therapeutic response of patients with juvenile derm...
The present guidelines on dermatomyositis (DM) represent an excerpt from the interdisciplinary S2k g...
Figure S2. Biological therapy: time to introduction and remission rate. Disease duration before intr...
Appendix of longitudinal analysis methods for prognosis study in rheumatic diseases. (DOCX 1112 kb
Detailed information on patterns in the use of high-dose glucocorticoid therapy in moderate juvenile...
CARRA survey: Use of Biologics in Juvenile Dermatomyositis. Appendix B Second CARRA JDM Survey: Use ...
Disease Characteristics of 45 Patients with Juvenile Dermatomyositis. (DOCX 27 kb
Additional file 1: Fig. 1s: Changes of BMI percentile in JDM patients over study duration (60 months...
Tables S1. Intravenous pulse methylprednisolone use and dosage. Table S2. Cyclophosphamide and oral ...
Additional file 2: Fig. 2s: Changes of Total body fat (TBF) percentile in JDM patients over study du...
Background: Juvenile dermatomyositis (JDM) is the most common inflammatory myopathy in childhood and...
Abstract Background Juvenile Dermatomyositis (JDM) is a rare pediatric autoimmune disease with broad...
Table with total number of AEs by MedDRA SOC for retrospective and prospective visits in the Pharmac...
Juvenile dermatomyositis (JDM) is a rare, severe, autoimmune disease characterized by a small-vessel...
Figure S1A. VAS and score of ISG15, HIF1α and VEGF in DM patients. “Severity” of tissue affection in...
Objective: To determine the clinical profile and therapeutic response of patients with juvenile derm...
The present guidelines on dermatomyositis (DM) represent an excerpt from the interdisciplinary S2k g...
Figure S2. Biological therapy: time to introduction and remission rate. Disease duration before intr...
Appendix of longitudinal analysis methods for prognosis study in rheumatic diseases. (DOCX 1112 kb